You are here: Industry Insights > Agenus

News List

Agenus BLA for Balstilimab as Treatment for Cervical Cancer Granted Priority Review by U.S. FDA americanpharmaceuticalreview
June 18, 2021
Agenus Inc., an immuno-oncology company with an extensive pipeline of agents including checkpoint antibodies, cell therapies, adjuvants, and vaccines that activate immune response to cancers and infections announced that the U.S. FDA accepted Agenus’ ...
Agenus and BMS Announce License for Anti-TIGIT Bispecific Antibody Program americanpharmaceuticalreview
May 19, 2021
Bristol-Myers Squibb Company and Agenus Inc. have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to Agenus’ proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a ...
Agenus Submits Balstilimab Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer americanpharmaceuticalreview
April 20, 2021
Agenus Inc., an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced the submission of a ...
Agenus Announces Positive Preliminary Results of iNKT Cell Therapy Trial in COVID-19 americanpharmaceuticalreview
February 09, 2021
Agenus has announced positive preliminary results from its Phase 1 trial of iNKT cell therapy in patients with moderate to severe symptoms of COVID-19 through its subsidiary, AgenTus Therapeutics.
Agenus Enters into Clinical Collaboration with Nelum for Zalifrelimab Combination americanpharmaceuticalreview
February 03, 2021
Agenus has entered into a clinical collaboration with Nelum to evaluate the safety and efficacy of zalifrelimab, Agenus’ anti-CTLA-4 antibody, in combination with NLM-001, Nelum’s small molecule hedgehog inhibitor, and chemotherapy for first-line ...
Agenus Announces Milestone Payment from Merck americanpharmaceuticalreview
November 23, 2020
Agenus announced that a milestone payment of $10M from Merck has been triggered with the advancement of an ILT4 antibody, MK-4830, into a Phase 2 clinical trial.
First patient dosed in COVID-19 trial with allogeneic cell therapy europeanpharmaceuticalreview
November 10, 2020
The first patient with COVID-19 has been administered agenT-797, an allogeneic cell therapy made by Agenus Inc.
Agenus Doses First COVID-19 Patient with iNKT Cell Therapy americanpharmaceuticalreview
November 05, 2020
Agenus announced the dosing of the first COVID-19 patient with agenT-797, an allogeneic cell therapy, through its subsidiary, AgenTus Therapeutics. The trial is being led by Dr. Koen van Besien at ...
FDA Clears IND for iNKT Cells to Treat COVID-19 Patients americanpharmaceuticalreview
June 11, 2020
Agenus announced the U.S. Food and Drug Administration’s (FDA) clearance of AgenTus' IND application for an allogeneic iNKT therapy.
Agenus Receives Fast Track Designation for Cervical Cancer Treatment americanpharmaceuticalreview
March 17, 2020
Agenus announced the U.S. Food and Drug Administration (FDA) has granted Agenus Fast Track designation for investigation of balstilimab [PD-1] in combination ...

Previous page 1 2 Next page